A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs KBP 042 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors KeyBioScience
- 17 Sep 2018 This trial was completed in Poland (end date: 2018-07-09), according to European Clinical Trials Database.
- 10 Sep 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated